Our findings collectively indicate that in germline BRCA ovarian cancer patients, PARPi treatments significantly elevate STAT3 activity in tumor cells and tumor-associated immune cells, including B cells, CD4+ and CD8+ T cells, and CAFs. The gene discussed is STAT3; the disease is ovarian cancer.